All In Biotech

Drug Trial Radar · NCT07231679

A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease

A Randomized, Placebo-Controlled, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, and Pharmacokinetics of IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

94

Planned (sponsor's estimate)

Start

Oct 30, 2025

Primary completion

Dec 2026

Study completion Apr 2027

Sponsor

Lead sponsor
Ingenia Therapeutics INCIndustry
Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to observe the safety of IGT-303 in healthy volunteers and participants with Chronic Kidney Disease. The main question it aims to answer is: Is IGT-303 safe as a single dose or multiple dose regimen when applied under the skin (subcutaneously (SC)) or to a vein (intravenously (IV)). Researchers will compare IGT-303 against a placebo to see if IGT-303 is safe for use. Participants will be assigned to either IGT-303 or placebo and assessed for safety and tolerability for the duration of the study.

Conditions

  • Healthy Volunteers
  • Chronic Kidney Disease

Interventions

  • IGT-303Drug

    IGT-303 administered via IV or SC

  • PlaceboDrug

    Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs), serious adverse events (SAEs), and treatment-emergent adverse events (TEAEs)Time frame: From Screening to Day 84.

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • Balboa Nephrology - Chula Vista

    Chula Vista, California · Not yet recruiting

  • Clinical Research of Central Florida

    Lakeland, Florida · Not yet recruiting

  • Piedmont HealthCare

    Statesville, North Carolina · Not yet recruiting

  • Wilmington Health

    Wilmington, North Carolina · Not yet recruiting

  • Nucleus Network

    Herston, Brisbane, Australia · Recruiting

  • Renal Research

    Gosford, New South Wales, Australia · Recruiting

  • Concord Repatriation General Hospital

    Sydney, New South Wales, Australia · Recruiting

  • University of the Sunshine Coast Clinical Trials-Southbank

    Morayfield, Queensland, Australia · Recruiting

  • University of the Sunshine Coast-Morayfield

    Morayfield, Queensland, Australia · Recruiting

  • Sunshine Hospital

    Saint Albans, Victoria, Australia · Recruiting

  • Pacific Clinical Research Network

    Takapuna, Auckland, New Zealand · Recruiting

  • Momentum Clinical Research

    Waikanae Beach, Kapiti Coast, New Zealand · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.